Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?Zacks Investment Research • 03/08/24
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsPRNewsWire • 03/06/24
Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should KnowZacks Investment Research • 02/21/24
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024PRNewsWire • 02/21/24
Inovio Pharmaceuticals, Inc. (INO) CEO Jacque Shea Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference TranscriptSeeking Alpha • 02/14/24
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferencePRNewsWire • 02/07/24
How Much Upside is Left in Inovio (INO)? Wall Street Analysts Think 223.72%Zacks Investment Research • 01/30/24
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion LeaderPRNewsWire • 01/22/24
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)PRNewsWire • 01/04/24
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval ProgramPRNewsWire • 01/03/24
Inovio shares rise after positive FDA feedback on RRP treatment candidateProactive Investors • 10/10/23
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval ProgramPRNewsWire • 10/10/23
Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 25th Annual Global Investment Conference (Transcript)Seeking Alpha • 09/12/23
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory PapillomatosisPRNewsWire • 09/07/23
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 08/29/23